Marathon Asset Management signed a deal to acquire Kaléo for $310 million in cash as the firm boosts its healthcare-oriented investments.
Richmond, Virginia-based Kaléo is a privately held pharmaceutical company that serves patients at risk for anaphylaxis and other serious life-threatening conditions. The deal will offer liquidity for Kaléo shareholders upon closing in a series of cash payments through 2023.
“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” said Dr. Evan Bedil, head of healthcare at Marathon. “We . . .
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators